Stock REGN REGENERON PHARMACEUTICALS, INC.
Add to a list

Connections Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 02:30:00 14/02/2026 am IST 		5-day change 1st Jan Change
803.17 USD +2.49% Intraday chart for Regeneron Pharmaceuticals, Inc. +2.93% +4.06%
13/02 HSBC Adjusts Price Target on Regeneron Pharmaceuticals to $990 From $985, Maintains Buy Rating MT
12/02 Regeneron Pharmaceuticals Insider Sold Shares Worth $1,585,058, According to a Recent SEC Filing MT

28

Listed companies

12

Private companies

116

Insiders

Relation chart of related listed companies: Regeneron Pharmaceuticals, Inc.

Active Relations

Past Relations

Related listed companies: Regeneron Pharmaceuticals, Inc.

NEUROCRINE BIOSCIENCES, INC.
Christine Poon
IONIS PHARMACEUTICALS, INC.
Hala Mirza
MERCK KGAA
David Weinreich
BAYER AG
Christian Rommel
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Craig Thompson
PRUDENTIAL FINANCIAL, INC.
Christine Poon
CYTOKINETICS, INCORPORATED
Robert Landry
OCULAR THERAPEUTIX, INC.
Namrata Saroj
HARROW, INC.
Greg DiPasquale
ARDELYX, INC.
Merdad Parsey
COHERUS ONCOLOGY, INC.
Denny Lanfear
IMMUNEERING CORPORATION
Harold Brakewood
CRISPR THERAPEUTICS AG
Christian Rommel
4D MOLECULAR THERAPEUTICS, INC.
Julie Clark
DENALI THERAPEUTICS INC.
David Schenkein
Marc Tessier-Lavigne
REPLIMUNE GROUP, INC.
Arleen Goldenberg
ANNEXIN PHARMACEUTICALS AB
Alain Thibault
TENAYA THERAPEUTICS, INC.
Catherine Stehman-Breen
DYNE THERAPEUTICS, INC.
Catherine Stehman-Breen
PRIME MEDICINE, INC.
David Schenkein
ROYALTY PHARMA PLC
Bonnie Bassler
SIONNA THERAPEUTICS, INC.
Marcella Ruddy
BAUSCH + LOMB CORPORATION
Manisha A. Narasimhan
ARRIVENT BIOPHARMA, INC.
Merdad Parsey
UPSTREAM BIO, INC.
Marcella Ruddy
ZURA BIO LIMITED
Neil Graham
ZYMEWORKS INC.
Robert Landry
CALCIMEDICA, INC.
Fred Middleton

Active Relations

Past Relations

Relationship chart for related private companies: Regeneron Pharmaceuticals, Inc.

Active Relations

Past Relations

Related private companies: Regeneron Pharmaceuticals, Inc.

Biotechnology Innovation Organization

Miscellaneous Commercial Services

N. Coles
David Schenkein
The Royal Society

Investment Trusts/Mutual Funds

Michael Brown
Joseph Goldstein
Marc Tessier-Lavigne
Bonnie Bassler
Howard Hughes Medical Institute, Inc.

Investment Trusts/Mutual Funds

Joseph Goldstein
Craig Thompson
Huda Zoghbi
National Academy of Sciences

Miscellaneous Commercial Services

P. Vagelos
Michael Brown
Joseph Goldstein
George Yancopoulos
Marc Tessier-Lavigne
Craig Thompson
Huda Zoghbi
Bonnie Bassler
American Academy of Arts & Sciences

Miscellaneous Commercial Services

P. Vagelos
Craig Thompson
Huda Zoghbi
Bonnie Bassler
National Academy of Medicine (United States)

Miscellaneous Commercial Services

P. Vagelos
Michael Brown
Joseph Goldstein
Marc Tessier-Lavigne
Craig Thompson
Huda Zoghbi
Bonnie Bassler
American Philosophical Society

Miscellaneous Commercial Services

P. Vagelos
Michael Brown
Marc Tessier-Lavigne
Bonnie Bassler
The Column Group LLC

Investment Managers

Michael Brown
Joseph Goldstein
Huda Zoghbi
The University of Texas Southwestern Medical Center

Other Consumer Services

Michael Brown
Joseph Goldstein
Checkmate Pharmaceuticals, Inc.

Robert Landry
Nouhad Husseini
Decibel Therapeutics, Inc.

Joseph LaRosa
Robert Landry
Nouhad Husseini
GanD, Inc.

George Sing
Robert Landry

Active Relations

Past Relations

Connection statistics

Active

Inactive

Listed companies

Private companies

Activities of related companies

Pharmaceuticals: Major7
Miscellaneous Commercial Services6
Investment Trusts/Mutual Funds2
Other Consumer Services1
Investment Managers1
Life/Health Insurance1
Biotechnology1

Countries of related companies

United States34
Germany2
United Kingdom1
Canada1
Sweden1
Switzerland1

Company Profile

Logo Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from collaboration agreements (51.1%): collaboration with Sanofi (80.3% of revenues), Bayer (19.4%) and other (0.3%); - revenues from product sales (30%); - revenues from sales of technology licenses and subcontracted research services (4.9%). At the end of 2025, the group had a portfolio of approximately 45 products in clinical development.
Employees
15,410
Sector
Pharmaceuticals
Calendar
20/02 -
More about the company
  1. Stock Market
  2. Equities
  3. REGN Stock
  4. Company Regeneron Pharmaceuticals, Inc.
  5. Connections

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States
United-States
Canada
Canada

MIDDLE EAST

Saudi Arabia
Saudi Arabia
United Arab Emirates
United Arab Emirates

EUROPE

France
France
Deutschland
Deutschland
Suisse
Suisse
Schweiz
Schweiz
Italia
Italia
Österreich
Österreich
België
België
Nederland
Nederland
España
España
Sverige
Sverige
United Kingdom
United Kingdom

APAC

Australia
Australia
India
India
Hong Kong
Hong Kong
United States

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition